Bevacizumab biosimilar (Huaota Biopharm/Shanghai Junshi Biosciences)

贝伐珠单抗生物类似药 (华奥泰生物/君实生物)

Report date: 2024/04/01 10:53:28

Base Information

Drug NameBevacizumab biosimilar (Huaota Biopharm/Shanghai Junshi Biosciences)

Drug Alias Name贝伐单抗生物仿制药（华奥泰生物/君实生物）贝伐珠单抗生物仿制药（华奥泰生物/君实生物）贝伐赛珠单抗生物仿制药（华奥泰生物/君实生物）贝伐人源化单抗生物仿制药（华奥泰生物/君实生物）阿瓦斯汀生物类似药（华奥泰生物/君实生物） +[8]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsColorectal Neoplasms

ATC CodeL01XC07